NCT03890289 2024-11-21
GAUDEALIS
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
Clinical Trials
10 trialsNCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT04699461 2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2 Terminated
NCT02536300 2023-08-14
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Gilead Sciences
Phase 3 Terminated
NCT02242045 2021-03-19
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 1 Completed
NCT02603445 2020-02-24
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Novartis
Phase 1 Completed
NCT01282424 2019-07-11
DELTA
Gilead Sciences
Phase 2 Completed
NCT02258529 2019-05-14
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences
Phase 2 Terminated
NCT01306643 2018-11-19
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Gilead Sciences
Phase 1/2 Completed
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated